BiotechTube

AmBisome

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Candidemia

Conditions

Candidemia, Invasive Candidiasis

Trial Timeline

May 1, 2007 → Jan 1, 2009

NCT ID
NCT00670657

About AmBisome

AmBisome is a approved stage product being developed by Gilead Sciences for Candidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00670657. Target conditions include Candidemia, Invasive Candidiasis.

What happened to similar drugs?

3 of 7 similar drugs in Candidemia were approved

Approved (3) Terminated (2) Active (3)
✅micafungin + Micafungin + CaspofunginAstellas PharmaApproved
✅MicafunginAstellas PharmaApproved
✅Anidulafungin + VoriconazolePfizerApproved
❌Anidulafungin/FluconazolePfizerPhase 3
🔄Anidulafungin + FluconazolePfizerPhase 3
🔄AnidulafunginPfizerPhase 3
🔄Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + PlaceboBasilea PharmaceuticaPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT00670657ApprovedCompleted
NCT00326157Phase 2Completed
NCT00362544ApprovedCompleted
NCT00158730Phase 3Completed

Competing Products

9 competing products in Candidemia

See all competitors
ProductCompanyStageHype Score
micafungin + Micafungin + CaspofunginAstellas PharmaApproved
43
MicafunginAstellas PharmaApproved
35
Anidulafungin/FluconazolePfizerPhase 3
32
Anidulafungin + VoriconazolePfizerApproved
43
Anidulafungin + FluconazolePfizerPhase 3
40
AnidulafunginPfizerPhase 3
40
Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + PlaceboBasilea PharmaceuticaPhase 3
41
APX001Basilea PharmaceuticaPhase 2
29
APX001Basilea PharmaceuticaPhase 2
29